Profil
Henrich R.
K.
Guntermann worked as a Director and President-Europe & Immunology Group at Nuvo Pharmaceuticals, Inc. from 2011 to 2016.
He also worked as a Director at Crescita Therapeutics, Inc. in 2016.
Guntermann holds a doctorate degree from Philipps University of Marburg.
Anciens postes connus de Henrich R. K. Guntermann
| Sociétés | Poste | Fin |
|---|---|---|
| CRESCITA THERAPEUTICS INC. | Directeur/Membre du Conseil | 29/09/2016 |
| NUVO PHARMACEUTICALS INC. | President | 16/12/2009 |
Formation de Henrich R. K. Guntermann
| Philipps University of Marburg | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CRESCITA THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Nuvo Pharmaceuticals, Inc.
 Nuvo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada. | Health Technology |